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According to the 2013 World Health Organization (WHO) global tuberculosis report, an estimated 
8.6 million new cases of tuberculosis (TB) were diag-
nosed and 1.3 million people died from TB in 2012, 
while the number of multidrug-resistant tuberculosis 
(MDR-TB) notifications reached almost 450 000.1 
Globally, 3.6% of new cases and 20% of previously 
treated cases were estimated to have MDR-TB,1 which 
represents one of the most dramatic global health 
challenges of the past few years.
The WHO revised definitions broadly classify 
smear-positive TB patients into ‘new’ and ‘retreat-
ment’ cases. ‘Retreatment’ or ‘previously treated’ pa-
tients, defined as having previously taken anti-tuber-
culosis drugs for 1 month, are further classified as 
‘relapse’, ‘treatment after failure’, ‘treatment after de-
fault (lost to follow-up)’ or ‘others’, patients who do 
not fit the standard case definition.2 Previously treated 
TB cases are a challenge for TB control services, as they 
need to be tested for drug resistance, require a longer 
duration of treatment and have poorer treatment 
outcomes.3
Sri Lanka is considered a low-burden TB country 
with low MDR-TB rates.4 In 2012, Sri Lanka reported a 
total number of 9343 TB cases (48 cases per 100 000 
population, estimated by the WHO at 66/100 000) and 
433 were retreatment cases. Also in 2012, 1329 pa-
tients were tested and five were confirmed as 
MDR-TB.5 According to the national TB control guide-
lines, all sputum samples of smear-positive retreat-
ment cases are investigated for resistance to first-line 
drugs, namely isoniazid (INH), rifampicin (RMP), 
streptomycin (SM) and ethambutol (EMB), through 
culture and drug susceptibility testing (CDST) using 
solid culture Löwenstein-Jensen medium, and are ini-
tiated on a TB retreatment regimen without waiting 
for the CDST results.5 Programme reviews and field 
visits have suggested operational issues in the manage-
ment of such cases in terms of timely investigation for 
first-line drug resistance and initiation of resistant pa-
tients on MDR-TB treatment. There is a concern that 
any lapse in this implementation strategy would affect 
the outcome of TB patients and lead to increased 
MDR-TB prevalence in the country.
We therefore conducted a study to determine the 
proportion of patients whose samples were sent for 
CDST, the delays encountered during the process, the 
CDST results describing the culture positivity rates 
and type of drug resistance and the treatment out-
comes of these patients.
METHODS
Study design
This was a retrospective cohort study.
Setting
Sri Lanka is an island divided in 26 health districts, 
with a population of about 20 million.6 Kalutara dis-
trict, with a mainly rural population of 1.2 million, is 
among the districts with the highest TB prevalence in 
Sri Lanka. The population has three main ethnicities; 
Sinhalese (87.1%), Tamil (3.9%) and Moor (8.7%).7 
The District Chest Clinic (DCC) in Kalutara, the only 
institution catering for TB patients in the district, has 
a caseload of approximately 700 per annum. The dis-
trict has six peripheral microscopy centres and a 
main centre at the DCC, all of which are involved in 
sputum smear microscopy for screening and 
follow-up.
All CDST of sputum and other specimens is per-
formed through the National Tuberculosis Reference 
Laboratory (NTRL), which is located on the premises 
of Welisara Chest Hospital, 65 km from the district TB 
centre. The NTRL undergoes quality control for drug 
susceptibility testing (DST) by the Supranational Labo-
ratory, Chennai, India, and the University of Antwerp 
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Setting: District Chest Clinic, Kalutara, Sri Lanka.
Objectives: To determine the coverage of culture and 
drug susceptibility testing (CDST), delays in CDST, treat-
ment initiation, obtaining CDST results and treatment 
outcomes of previously treated tuberculosis (TB) patients.
Design: Retrospective cohort study involving review of 
records and reports. All previously treated TB patients 
from January 2008 to June 2013 were included in the 
study.
Results: Of 160 patients, 126 (79%) samples were sent 
for CDST; 79 (63%) were culture-positive and no multi-
drug-resistant (MDR) TB cases were reported. Respec-
tively 9% and 15% of patients experienced a delay in 
sending samples (median delay 21 days) and receiving 
CDST reports (median delay 71 days), while 20% experi-
enced delays in initiating the retreatment regimen (me-
dian delay 11.5 days). The cohort recorded an 82% treat-
ment success rate.
Conclusion: Of all retreatment patients, only 79% were 
tested for CDST and there were sizeable delays in sample 
transportation and treatment initiation. Possible ways for-
ward to strengthen the programme are discussed.
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Laboratory, in Antwerp, Belgium, a WHO Collaborat-
ing Centre.
Two samples are collected for culture from each pa-
tient over two consecutive days. They are refrigerated 
at the district chest clinic and sent to the NTRL twice a 
week in a cold box with a messenger, who travels by 
bus. Appropriate measures, such as sealing the cap 
with adhesive tape and covering the sealed bottle, are 
taken to prevent spillage and contamination during 
transportation. The results are sent to the respective 
districts by the laboratory by messenger sent from the 
districts or by post. Patients resistant to INH and RMP 
are initiated on an MDR-TB regimen; otherwise they 
are continued on the retreatment regimen which in-
cludes 2SHRZE/1HRZE/5HRE* for a period of 8 months. 
The drugs are provided under daily directly observed 
treatment (DOT), as per the WHO recommended strat-
egy adopted in 2006.
Operationally, the following were considered as de-
lays in our study: 1) 5 days for sending the samples to 
CDST (5 days was taken as the operational norm, as 
samples are sent to the NTRL twice a week); 2) 65 
days for receiving the CDST report from the Central 
Reference Laboratory, as it takes 8 weeks of incubation 
to report a negative culture; and 3) 5 days for initiat-
ing a Category II treatment regimen, as it takes a few 
days for patients who are diagnosed at the peripheral 
microscopy centres to attend the DCC, and two sam-
ples for CDST are taken over two consecutive days from 
each patient before initiating the retreatment regimen.
Study population
All retreatment smear-positive pulmonary TB patients 
registered in the district TB register, Kalutara district, 
during the period from 1 January 2008 to 30 June 2013 
were included in the study.
Variables, data collection and validation
The variables included in the study were type of re-
treatment, CDST results, treatment outcomes and days 
taken to establish diagnosis, treatment initiation, sam-
ple sending and declaration of results. All the data 
were collected from the existing district TB register and 
laboratory CDST registers and double-checked with 
the original patient treatment cards. The data were col-
lected in a customised data collection proforma, dou-
ble-entered into EpiData (version 3.1, EpiData Associa-
tion, Odense, Denmark) and cross-validated.
Analysis and statistics
Relative proportions and incurred delays were assessed 
through simple summary statistics using EpiData Analy-
sis (v.2.2.1.171).
Ethics issues
Ethics clearance was obtained from the Ethics Advisory 
Group of the International Union Against Tuberculosis 
and Lung Disease, Paris, France; the National TB Con-
trol Programme (NPTCCD), Sri Lanka; and the Ethics 
Approval Committee of Sri Jayawardenapura Univer-
sity, Sri Lanka.
* S = streptomycin; H = isoniazid; R = rifampicin; Z = pyrazinamide; 
E = ethambutol. Numbers before the letters indicate the duration 
of the phase of treatment in months. 
RESULTS
During the study period, 160 previously treated TB pa-
tients were registered under the programme; 39 of 
these were failures, 95 were relapses and 25 were treat-
ment after default. Of the 79% of patient sputum sam-
ples sent for CDST, 63% were culture-positive, none 
was resistant to INH and RMP, four were non-tubercu-
losis mycobacteria, and results were missing for 18 
(Figure). The DST results showed sizeable rates of mono-
resistance (12%) and polyresistance (7%) among the 
cultures. Monoresistance was mainly found to EMB or 
SM, while polyresistance was mainly found to INH+ 
SM, or EMB+SM (Table 1).
Of all the samples sent for CDST, delays occurred in 
sending for 9% and in receiving the reports from the 
NTRL for 15%. A delay was experienced by 20% of pa-
tients in initiating Category II treatment; this was 
more marked among treatment after failure patients 
(36%) (Table 2). The median delay for sending samples 
was 21 days (range 8–262), for receiving reports 71 
days (range 66–161) and for treatment initiation 11.5 
days (range 6–185).
The overall treatment success for the cohort that 
completed treatment was 82%, with eight patients still 
on treatment irrespective of their culture results. Four 
patients with contaminated or unreported culture re-
sults had unfavourable outcomes (Table 3).
DISCUSSION
This is the first study conducted in Sri Lanka in a pro-
gramme setting to describe the delays in investigating 
drug resistance and treatment outcomes among previ-
ously treated TB patients. We found that about 80% of 
the patient samples reached the NTRL, which is better 
than in similar studies conducted in India (69%), Cam-
bodia (46%) and China (42%).8–10 This illustrates the 
commitment of the programme in managing previ-
ously treated TB patients. There were no MDR-TB cases 
among the cohort. Twenty per cent of the previously 
treated TB patients experienced delay in initiating 
their Category II regimen.
The study finding has the following programme im-
plications. First, although Sri Lanka is a small country 
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FIGURE Flow chart showing previously treated patients 
registered in Kalutara District, Sri Lanka, January 2008–
June 2013. CDST = culture and drug susceptibility testing; 
DST = drug susceptibility testing.
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with a low burden of TB and a well-established national TB con-
trol programme, and TB patients are low in number, nearly 20% 
of patient samples had not reached the CDST laboratory, and 23% 
of the DST reports were not available in the patient records or reg-
isters in the clinic. There is scope and an immediate need for the 
programme to strengthen its supervision and monitoring system 
so as to identify previously treated TB patients effectively, estab-
lish mechanisms for rapid transport of sputum samples from the 
field, and enhance accurate record keeping. Continued involve-
ment and coordination is needed from the general health system 
to monitor the process. Creation of a post for a mid-level pro-
gramme officer at sub-district level would be a feasible strategy for 
strengthening the system.
Second, 34% of samples were culture-negative, which could be 
a consequence of storage and twice-weekly transport of samples 
to the NTRL. Such issues could be addressed by finding ways ei-
ther to implement a daily sample transport or to decentralise the 
facility, although the latter option is unlikely to be cost-effective. 
However, culture results among patients treated after relapse and 
after default (culture negativity 16% and 10%, respectively) sug-
gest that poor storage and transport conditions are unlikely to 
fully explain the overall 34% negativity rate. The cohort of treat-
ment after failure patients was the main contributor to overall 
culture negativity, with 85% of this group culture-negative, prob-
ably due to high rates of false treatment failures resulting from er-
roneous detection of dead bacilli in the laboratory. Further studies 
are required to identify more effective ways of diagnosing and rul-
ing out such patients, such as by introducing tests such as fluores-
cein diacetate vital staining (FDA).11
Third, no MDR-TB cases were detected in this cohort. In con-
trast, neighbouring South-East Asian countries such as India and 
Bangladesh have a high prevalence of MDR-TB.12–14 However, our 
findings were similar to those of other drug resistance studies 
conducted in Sri Lanka.15 While the culture positivity rate was 
similar to those in other studies in the world, there was no INH 
and RMP resistance.8,12 This raises speculation about the quality 
of the sputum samples collected, transported and processed at the 
laboratory. It is essential that the operating procedures of the 
CDST laboratory be certified and closely monitored by a 
WHO-identified Supranational Reference Laboratory. Consider-
able mono- and polyresistance was observed in the study. To ad-
dress these, the programme should create effective collaboration 
with the private sector and emphasise the International Standards 
of TB Care (ISTC) for diagnosis and treatment,16 possibly by roll-
ing out rapid molecular tests such as Xpert® MTB/RIF (Cepheid, 
Inc, Sunnyvale, CA, USA), which was introduced only recently 
and remains limited to a small proportion of patients, and by 
strengthening DOT in the country.15
Fourth, the delays in initiation of Category II treatment in 
20% of the patients and in 36% of failure patients is of concern, 
as these are cases with a high potential for developing drug resis-
tance. Under the programme, although there are no specific 
guidelines on when treatment should be started, patients are con-
ventionally initiated on treatment within the first 5 days. Imme-
diate measures need to be taken by the programme to identify the 
operational issues and provide feasible solutions.
Fifth, the treatment success rate of previously treated TB cases, 
reported as 82%, with a death rate of 6%, is relatively satisfactory 
when compared to studies conducted in Malawi, for example, 
where the treatment success rate and death rate were 75% and 
14%, respectively.17 This high success rate could be due to the 
lower prevalence and the well-established programme, and man-
agers should not be complacent. The death rate may be due to the 
association of TB with other co-morbidities. The prevalence of 
human immunodeficiency virus (HIV) infection is low in the 
country and there is no established TB-HIV co-infection. After 
2012, the programme nevertheless established a policy of rou-
tinely screening all TB patients for HIV at chest clinics. The preva-
lence of diabetes is high in the general population, and the pro-
gramme needs to conduct operational feasibility studies for a 
routine screening policy for TB patients for diabetes.18
The strengths of the study are that it was conducted in a pro-
TABLE 1 Culture and DST results of previously treated TB patients 
from Kalutara District, Sri Lanka, 2008–2013
Failure 
n (%)
Relapse
n (%)
Treatment  
after default
n (%)
Total
n (%)
Culture result
 Negative 29 (85) 12 (16) 2 (10) 43 (34)
 Positive 5 (15) 59 (81) 15 (79) 79 (63)
 Contaminated 0 (0) 2 (3) 0 (0) 2 (2)
 Not reported 0 (0) 0 (0) 2 (10) 2 (2)
  Total 34 (100) 73 (100) 19 (100) 126 (100)
DST results
 Susceptible to all drugs 1 (33) 31 (52) 11 (73) 43 (54)
 Monoresistance 0 (0) 7 (12) 2 (13) 9 (11)
 EMB 0 (0) 2 (3) 2 (13) 4 (5)
 SM 0 (0) 5 (8) 0 (0) 5 (6)
 Polyresistance 0 (0) 5 (8) 0 (0) 5 (6)
 INH+SM 0 (0) 2 (3) 0 (0) 2 (2)
 INH+EMB 0 (0) 1 (2) 0 (0) 1 (1)
 EMB+SM 0 (0) 2 (3) 0 (0) 2 (2)
 NTM 0 (0) 4 (7) 0 (0) 4 (5)
 Not available 2 (67) 12 (20) 2 (13) 18 (23)
  Total 3 (100) 59 (100) 15 (100) 79 (100)
DST = drug susceptibility testing; EMB = ethambutol; SM = streptomycin; INH = iso-
niazid; NTM = non-tuberculous mycobacteria.
TABLE 2 Delays in sending samples, receiving reports and initiating 
treatment among previously treated TB patients in Kalutara District, 
Sri Lanka, 2008–2013
n (%)
Delays in sending samples for CDST
 No delay (5 days) 111 (91)
 Delay  (5 days) 10 (9)
  Total 121* (100)
Delay in receiving reports of CDST
 No delay (65 days) 88 (85)
 Delay (65 days) 15 (15)
  Total 103† (100)
Delay in initiating Category II regimen
 No delay (5 days) 98 (80)
 Delay (5 days) 24 (20)
  Total 122‡ (100)
* Of 126 patients for whom CDST results were sent, 5 were excluded as the CDST 
sent dates were not available.
† Of 121 patients for whom CDST sent dates were available, 18 were excluded as the 
CDST result receiving dates were not available.
‡ 36 patients were excluded as the date of diagnostic smear microscopy was not 
recorded.
TB = tuberculosis; CDST = culture and drug susceptibility testing.
Public Health Action Retreatment TB in Sri Lanka  108
gramme setting and reflects the reality in the field, a large number 
of records were verified from the past 5 years and the Strengthen-
ing the Reporting of Observational Studies in Epidemiology 
(STROBE) guidelines were adhered to. The study has a number of 
limitations: as in any record-based review, there is always incom-
plete data recording and inaccuracies, and the CDST results and 
TB treatment outcome were not available for a number of pa-
tients. In addition, the relatively high number of culture-positive 
patients with drug resistance patterns other than INH and RMP 
remains unexplained.
To conclude, in the national TB control programme of Sri 
Lanka, substantial numbers of previously treated TB patients are 
not tested for drug resistance, and there is a sizeable delay in ini-
tiation of the Category II treatment regimen. The programme 
must implement measures to enhance monitoring and supervi-
sion, such as creating a post for a mid-level programme officer at 
sub-district level, transporting specimens in a timely fashion and 
adopting new diagnostic measures to overcome these challenges.
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Contexte  :  Dispensaire de pneumologie du district de Kalutara, Sri 
Lanka.
Objectif  :  Déterminer la couverture du test de culture et de sensibilité 
aux médicaments (CDST), les délais des tests de résistance aux 
médicaments, de mise en œuvre du traitement et d’obtention des 
résultats du CDST ainsi que les résultats du traitement chez des 
patients tuberculeux déjà traités auparavant.
Schéma  :  Etude rétrospective de cohorte par revue de dossiers et de 
rapports. Tous les patients tuberculeux de janvier 2008 à juin 2013 
déjà traités ont été inclus dans l’étude.
Résultats  :  Sur 160 patients, 126 (79%) ont été référés pour un CDST ; 
79 (63%) avaient une culture positive et il n’y a eu aucun cas de TB-
MDR. Environ 9% et 15% des patients, respectivement, ont eu un 
retard d’expédition des échantillons (retard médian 21 jours) et de 
réception du rapport du CDST (retard médian 71 jours), tandis que 
20% ont subi un retard de mise en œuvre de la reprise du traitement 
(retard médian 11,5 jours). Le taux de succès thérapeutique de la 
cohorte atteignait 82%.
Conclusion  :  Parmi tous les patients en retraitement, seulement 79% 
ont bénéficié d’un CDST et il y a eu des retards considérables dans le 
transport des échantillons et la mise en œuvre du traitement. Des 
discussions sont en cours afin de renforcer le programme.
Marco de referencia: El consultorio distrital de neumología de 
Kalutara, en Sri Lanka.
Objetivos: Determinar la cobertura con la culture y las pruebas de 
sensibilidad a los medicamentos antituberculosos (CDST), el retraso 
en el análisis de la farmacorresistencia, el comienzo del tratamiento y 
la obtención del resultado del CDST y los desenlaces terapéuticos de 
los pacientes con diagnóstico de tuberculosis (TB) y antecedente de 
tratamiento previo.
Método: Se llevó a cabo un estudio retrospectivo de cohortes con 
análisis de las historias clínicas y los informes de laboratorio. Se 
incluyeron en el estudio todos los pacientes tuberculosos atendidos 
entre enero del 2008 y junio del 2013 que habían recibido 
tratamiento antituberculoso.
Resultados: De los 160 pacientes incluidos en el estudio se enviaron 
126 muestras para CDST (79%); en 79 muestras se obtuvo un cultivo 
positivo para TB (63%) y no se notificaron casos de 
multidrogorresistencia. Se observó retraso en el envío de las muestras 
en el 9% de los casos (mediana del retraso 21 días) y en el 15% de 
los pacientes hubo retraso en la obtención de los resultados del CDST 
(mediana del retraso 71 días); en 20% de los pacientes se retrasó el 
comienzo del régimen de retratamiento (mediana del retraso 11,5 
días). La tasa de éxito terapéutico en la cohorte estudiada fue 82%.
Conclusión: De todos los pacientes en retratamiento, se practicaron 
CDST solo en 79% de los casos y se observaron retrasos considerables 
en el transporte de las muestras y el comienzo del tratamiento. En el 
artículo se proponen métodos encaminados a fortalecer el programa.
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